Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2018 - 2025)

Protalix BioTherapeutics has reported Long-Term Deferred Tax over the past 4 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $2.5 million for Q4 2025, down 11.9% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (down 11.9% YoY), and the annual figure for FY2025 was $2.5 million, down 11.9%.
  • Long-Term Deferred Tax for Q4 2025 was $2.5 million at Protalix BioTherapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for PLX hit a ceiling of $3.3 million in Q2 2024 and a floor of $2.5 million in Q4 2025.
  • Median Long-Term Deferred Tax over the past 3 years was $3.0 million (2025), compared with a mean of $3.0 million.
  • Biggest five-year swings in Long-Term Deferred Tax: grew 5.4% in 2024 and later fell 17.01% in 2025.
  • Protalix BioTherapeutics' Long-Term Deferred Tax stood at $3.1 million in 2023, then decreased by 7.63% to $2.9 million in 2024, then decreased by 11.9% to $2.5 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $2.5 million (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.